Tradestie Institutional Equity Comparison Engine

IMDX vs MYGN โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-19 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

MYGN Overall Edge

MYGN Captures Institutional Edge (4โ€“0 Pillars ยท 7โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Myriad Genetics Inc (MYGN) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, IMDX trades at N/M Forward P/E with -1883.2% operating margin (+115.0% YoY revenue) versus MYGN at 54.0x Forward P/E and -13.3% operating margin (-1.5% YoY). In options structure, IMDX sits in BREAKDOWN (12th %ile IV; Dealer Gamma Walls on Pro) against MYGN sits in CONSOLIDATION (22nd %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner MYGN
IMDX N/M vs MYGN 54.0x Fwd P/E
Growth & Margin Winner MYGN
Op Margin -1883.2% vs -13.3% ยท YoY +115.0% vs -1.5%
Momentum & Technical Winner MYGN
1Y -73.8% vs -16.4% ยท 52W Pos 3% vs 52%
Options & Structure Winner MYGN
BREAKDOWN (12th %ile IV) vs CONSOLIDATION (22nd %ile IV)
IMDX NASDAQ
Insight Molecular Diagnostics Inc. Common Stock
In Vitro & In Vivo Diagnostic Substances
$1.66
+4.4% 1D
Market Cap $52.1M
1M Return -45.03%
1Y Return -73.78%
Forward P/E N/M
Unified AI Score
45.5 / 100 HOLD
Tech 50.0 Fund 40.0 Flow 58.0 Mom 40.0
MYGN NASDAQ
Myriad Genetics Inc
In Vitro & In Vivo Diagnostic Substances
$5.54
+0.18% 1D
Market Cap $530.4M
1M Return -0.54%
1Y Return -16.44%
Forward P/E 54.0x
Unified AI Score
45.4 / 100 HOLD
Tech 42.0 Fund 48.0 Flow 59.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: IMDX -73.78% MYGN -16.44% Spread: +57.34 pp (MYGN Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period IMDX Revenue MYGN Revenue IMDX Op. Margin MYGN Op. Margin Margin Edge
FY2018 N/A $740M N/A 16.4% MYGN
FY2019 N/A $850M N/A 0.9% MYGN
FY2020 $0M $560M -2443.3% -52.0% MYGN
FY2021 $0M $690M -2444.3% -27.6% MYGN
FY2022 $0M $680M -1878.6% -20.7% MYGN
FY2023 $0M $750M -1672.4% -34.2% MYGN
FY2024 $0M $840M -3245.1% -14.7% MYGN
FY2025 $0M $820M -1260.8% -47.0% MYGN

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: IMDX (2) vs MYGN (7)
Institutional Metric IMDX MYGN Criterion Row Winner
Market Capitalization Scale $52.1M $530.4M Larger Scale MYGN
Trailing P/E Ratio Valuation N/M 54.0x Lower Multiple MYGN
Forward P/E Ratio Valuation N/M 54.0x Lower Multiple MYGN
Revenue Growth (YoY) Growth +115.0% -1.5% Higher Growth IMDX
Operating Margin (TTM) Profitability -1883.2% -13.3% Higher Margin MYGN
Net Profit Margin Profitability 0.0% -16.1% Higher Margin IMDX
Return on Equity (ROE) Capital Efficiency -23603.1% -40.2% Higher ROE MYGN
52-Week Range Position Momentum 3% ($2โ€“$8) 52% ($3โ€“$8) Stronger Trend MYGN
Beta / 30D Volatility Risk Regime 2.91ฮฒ ยท 76% Vol 0.63ฮฒ ยท 54% Vol Lower Realized Risk MYGN
Unified Institutional Score Composite Signal 45.5 / 100 (HOLD) 45.4 / 100 (HOLD) Higher Composite Tie

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full IMDX vs MYGN Buy Guide
IMDX BREAKDOWN
117d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 12th %ile
IV Regime Compressed (<25th %ile)
Live IMDX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
MYGN CONSOLIDATION
15d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 22nd %ile
IV Regime Compressed (<25th %ile)
Live MYGN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither IMDX nor MYGN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.